GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chordia Therapeutics Inc (TSE:190A) » Definitions » Net Income Including Noncontrolling Interests

Chordia Therapeutics (TSE:190A) Net Income Including Noncontrolling Interests : 円-1,024.52 Mil (TTM As of Feb. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Chordia Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Chordia Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Feb. 2025 was 円0.00 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Feb. 2025 was 円-1,024.52 Mil.

Chordia Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Chordia Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordia Therapeutics Net Income Including Noncontrolling Interests Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Net Income Including Noncontrolling Interests
-527.11 -1,779.06 223.34 -1,827.13

Chordia Therapeutics Quarterly Data
Aug21 Aug22 May23 Aug23 May24 Aug24 Feb25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial - -524.84 -374.87 -649.65 -

Chordia Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,024.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Chordia Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Chordia Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chordia Therapeutics Inc (TSE:190A) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
TSE:4978 TSE:4579 TSE:4588 TSE:4599 TSE:7776 TSE:4880 TSE:4888 TSE:7096 TSE:4583 TSE:206A VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Website
https://www.chordiatherapeutics.com
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.

Chordia Therapeutics Headlines

No Headlines